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Abstract
Psoriasis is an immune-mediated chronic inflammatory skin disease, characterized by epidermal hyperplasia and infiltration
of leukocytes into the dermis and epidermis. IL-23 is expressed in psoriatic skin, and IL-23 injected into the skin of mice
produces IL-22-dependent dermal inflammation and acanthosis. The chemokine receptor CCR2 has been implicated in the
pathogenesis of several inflammatory diseases, including psoriasis. CCR2-positive cells and the CCR2 ligand, CCL2 are
abundant in psoriatic lesions. To examine the requirement of CCR2 in the development of IL-23-induced cutaneous
inflammation, we injected the ears of wild-type (WT) and CCR2-deficient (CCR2
2/2) mice with IL-23. CCR2
2/2 mice had
increased ear swelling and epidermal thickening, which was correlated with increased cutaneous IL-4 levels and increased
numbers of eosinophils within the skin. In addition, TSLP, a cytokine known to promote and amplify T helper cell type 2
(Th2) immune responses, was also increased within the inflamed skin of CCR2
2/2 mice. Our data suggest that increased
levels of TSLP in CCR2
2/2 mice may contribute to the propensity of these mice to develop increased Th2-type immune
responses.
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Introduction
Activated T cells and the cytokines they produce are thought to
drive the pathogenesis of psoriasis [1]. Cytokines secreted by CD4
+
T cells stimulate keratinocytes to proliferate and recruit in-
flammatory cells into the skin, promoting epidermal hyperplasia
and inflammation. Because CD4
+ T cells producing the T helper
cell type 1 (Th1) cytokine IFN-c are present in large numbers
within psoriatic plaques [2], Th1 cells have long been considered
the principal mediators of disease development. More recently,
a role for Th17 cells in psoriasis has been recognized. Th17
cytokines, including IL-17A, IL-17F, and IL-22, are found at
higher levels in psoriatic skin lesions than in non-psoriatic and
normal skin [3,4]. Additionally, IL-23, a Th17 growth and
differentiation factor and its receptor are increased in psoriatic
lesions [4,5,6]. Moreover, injection of wild-type (WT) mice with
IL-23 reproduces several aspects of disease, including epidermal
acanthosis, hyperkeratosis and a mixed dermal inflammatory
infiltrate that includes mononuclear cells and granulocytes–the
majority of which are neutrophils [7,8,9]. Finally, recent clinical
data demonstrate a critical role for Th17 cytokines. Immunothera-
pies using antibodies targeting IL-17 [10,11,12] or IL-12/IL-23
[13,14,15,16] are effective psoriasis treatments.
Several data suggest that chemokines and their receptors
regulate the pathogenesis of inflammatory diseases, including
psoriasis by regulating the recruitment of leukocytes into affected
tissues. Th17 cells express the chemokine receptor, CCR6
[8,17,18,19,20], and recent studies demonstrate that the CCR6
ligand, CCL20 is up-regulated in psoriatic plaques [18,21]. The
finding that CCR6-deficient mice fail to develop psoriasiform
pathology following intradermal injection with IL-23 supports
a critical role for CCR6 in this inflammatory skin disorder [9].
The expression of many other chemokines within psoriatic lesions
suggests that additional chemokine-driven mechanisms may also
regulate disease development.
CCR2 has been implicated in the pathogenesis of several
inflammatory diseases, and CCR2 antagonists have been de-
veloped. CCR2 is expressed on activated T cells–including Th17
cells [22,23], as well as monocytes, macrophages, immature
dendritic cells, cd T cells and NK cells [24]. CCR2 binds multiple
murine chemokine ligands: CCL2 (MCP-1), CCL7 (MCP-3) and
CCL12 (MCP-5) [25]. CCL2 is expressed at high levels in
psoriatic plaques by keratinocytes [26,27], suggesting a potential
role for CCR2 in psoriasis pathogenesis. A requirement for CCR2
in the development of Th17-mediated autoimmune inflammation
has been demonstrated [28,29]; EAE disease pathology in CCR2-
deficient (CCR2
2/2) mice is ameliorated. Protection from EAE is
associated with a decreased IFN-c response [28], although IL-17
and IL-22 cytokine production was not measured in these studies.
In contrast, in a mouse model of collagen-induced arthritis, disease
severity was exacerbated in CCR2
2/2 mice, and this correlated
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disease model, CCR2-deficiency may have an inflammatory or
anti-inflammatory effect.
Recent studies have demonstrated that skewing CD4
+ T cell
phenotype within psoriatic plaques to a Th2-type immune
response can ameliorate disease [31,32,33]. Treatment of psoriasis
patients with subcutaneous injections of IL-4 polarizes lesional T
cell responses to a Th2-type and decreases psoriasis severity [31].
Similarly, transdermal delivery of IL-4 expression plasmid
ameliorates disease in a mouse model of psoriasis [32,33]. Thus,
induction of a Th2 phenotype of skin infiltrating lymphocytes
correlates with disease improvement. In several models of
inflammation, CCR2 blockade blunts Th1-type immune responses
and enhances Th2-type immune responses. Studies using mouse
models of infection [34], inflammation [28,35], and graft rejection
[36] have demonstrated that CCR2-deficient (CCR2
2/2) mice
exhibit enhanced Th2-type responses with increased production of
IL-4 and IL-5, but decreased production of IFN-c. Given this bias
toward Th2 immunity in the absence of CCR2 signaling, and
a potential role for CCR2 in the pathogenesis of psoriasis, we
sought to examine whether CCR2-deficient mice are resistant to
the development of IL-23-induced psoriasis.
To test the hypothesis that CCR2 is required for the
development of psoriasis, we injected WT and CCR2
2/2 mice
intradermally with IL-23. We found that the skin of CCR2
2/2
mice actually becomes more inflamed than that of WT mice, with
increased ear swelling and epidermal thickening. Further, instead
of psoriasis-like inflammation seen in WT mice, IL-23-induced
cutaneous inflammation in CCR2
2/2 mice resembled atopic
dermatitis. This inflammation was associated with an increased
Th2-type immune response. Although comparable numbers of IL-
4-secreting CD4
+ T cells were present in the draining lymph node
and inflamed skin of WT and CCR2
2/2 mice, increased numbers
of eosinophils, mast cells and increased expression of IL-4 and
TSLP were detected within IL-23 injected CCR2
2/2 skin.
Materials and Methods
Mice
CCR2
2/2 mice [37] on a C57Bl/6 background were bred at
Massachusetts General Hospital and housed in a specific patho-
gen-free microisolator environment. C57Bl/6 mice were obtained
from the Jackson Laboratory. All experiments were performed
according to protocols approved by the Massachusetts General
Hospital Subcommittee on Research Animal Care (OLAW
Number: A3596-01).
Intradermal IL-23 Injections and Ear Swelling
Measurement
Cutaneous inflammation was induced by injecting the ears of
anesthetized mice every other day with 20 mL PBS alone or
containing 500 ng IL-23 (R&D Systems) using a 30-gauge needle
attached to a 50 mL Hamilton syringe every other day for ten days.
Ear swelling was measured each day immediately before injection,
starting on day 0. Ear measurements were made using a pocket
thickness gauge (Mitutoyo USA, Aurora, IL).
Histology, Measurement of Epidermal Thickness and
Eosinophil, Neutrophil and Mast Cell Quantitation
For histological assessment, ears were isolated and placed in
10% formalin. Formalin preserved ear skin was embedded in
paraffin and sections were stained with H&E. Images were
acquired and an investigator blinded to the genotype of the
animals determined the percent of eosinophils or neutrophils
among total leukocytes. 5 mm sections were stained with toluidine
blue for mast cell quantitation. Epidermal thickness was evaluated
using NIS-Elements software, and was calculated as: the area of
the epidermis/the length of the epidermis.
Fluorescence Immunohistology
Fluorescence immunohistology was performed on 10 mm frozen
ear skin sections. The sections were air dried for 10 minutes, fixed
in 4% paraformaldehyde for 8 minutes, and blocked with PBS
containing 5% FBS and 2 mg anti-CD16/CD32 (Biolegend) for 30
minutes at room temperature. Sections were then washed twice in
PBS 0.1% Tween and stained overnight with 1 mg of an affinity
purified polyclonal antibody to mouse TSLP (R & D Systems,
BAF555) diluted in PBS 0.1% saponin at 4uC. After washing with
PBS 0.1% Tween on ice, sections were stained with 1 mgo f
AlexaFluor 488-conjugated donkey anti-goat IgG (Invitrogen) for
1 hour at room temperature. After again washing with PBS 0.1%
Tween, sections were then stained with 1 mg/mL Hoescht in PBS
for 5 minutes. Finally, sections were washed in PBS, mounted with
ProLong Gold Antifade Reagent (Invitrogen), and examined
under a fluorescence microscope.
Processing of Ear Skin and Lymph Nodes for ex vivo
Stimulation and Flow Cytometry
Injected ears were isolated and minced. Ear skin was then
digested for 1 hour at 37uC in 5 mL HBSS containing 1 mg/mL
collagenase D (Sigma). Cells were then filtered through 70 mm
nylon mesh and washed in complete RPMI before stimulation.
Lymph nodes were disrupted using a 1 mL syringe plunger in
complete RPMI. Recovered leukocytes were passed through wire
mesh to obtain single cell suspensions. Samples were counted using
a hemacytometer.
Intracellular Staining
Intracellular cytokine staining for IL-4 was performed after
in vitro activation with PMA (50 ng/mL) and ionomycin (500 ng/
mL) for five hours at 37uC. GolgiPlug (BD Biosciences) was added
for the last four hours of stimulation. After stimulation, cells were
incubated with Fc block (Biolegend) and stained with antibodies
directed against CD3 and CD4. Cells were then fixed and
permeabilized using Fix and Perm cell fixation and permeabiliza-
tion kit (Invitrogen) and stained with antibody against IL-4.
RNA Isolation and qPCR
Total RNA was isolated from mouse skin, and quantitative PCR
was performed as described [38] with the Mx4000 Multiplex
Quantitative PCR System (Stratagene). Primer sequences used for
qPCR of b2m and CCL7 [39]; IL-4, IL-5, IL-13, IFN-c and IL-25
[40]; IL-17A, IL-17F, and IL-22 [41] have been published. The
following additional primer pairs were used: CCL2 F-TGG CTC
AGC CAG ATG CAG T and R-TTG GGA TCA TCT TGC
TGG TG; CCL12 F-GCT GGA CCA GAT GCG GTG and R-
CCG GAC GTG AAT CTT CTG CT; TSLP F-ACG GAT
GGG GCT AAC TTA CAA and R-AGT CCT CGA TTT GCT
CGA ACT.
TSLP Tissue Lysate ELISA
Ear skin was transferred into T-PER tissue protein extraction
reagent (Thermo Scientific) containing a protease inhibitor
cocktail (Roche) and homogenized using a Polytron (Kinemati-
ca:AG). Protein concentration was quantified using a BCA protein
quantification assay. ELISA for TSLP protein was performed
according to the manufacturer’s instructions (R&D Systems).
IL-23 Induces Th2 Inflammation in CCR2
2/2 Mice
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Comparisons were analyzed for statistical significance by
Student’s t-test with Microsoft Excel software, with P,0.05 being
considered significant.
Results
IL-23-induced Cutaneous Inflammation is More Severe in
CCR2
2/2 Mice than in WT Mice
Expression of the CCR2 ligand, CCL2 by basal keratinocytes
within psoriatic plaques has been detected [26,27], suggesting
a role for CCR2 in psoriasis pathogenesis. To determine the
requirement of CCR2 for development of psoriasis, we examined
whether CCR2
2/2 mice are protected from the development of
IL-23-induced psoriatic inflammation. We injected WT and
CCR2
2/2 mice intradermally in the ear with IL-23 every other
day. As has been reported previously, WT mice develop severe ear
swelling following intradermal IL-23 injection [7,8,9]. Ear
thickness increased by more than 150 mm compared with PBS-
injected WT control mice twelve days after initiation of IL-23
injections (Figure 1). Contrary to our hypothesis, CCR2
2/2 mice
actually developed more severe ear swelling than WT mice.
Average ear thickness of CCR2
2/2 mice increased more than
300 mm on day 12 (Figure 1).
CCR2
2/2 Mice Exhibit Increased Epidermal Thickness and
Tissue Eosinophilia
To further characterize the increased ear swelling observed in
CCR2
2/2 mouse ears, we examined H & E stained skin sections.
WT mice injected intradermally with IL-23 exhibit several features
of psoriasis, including epidermal acanthosis, hyperkeratosis and
a mixed dermal inflammatory infiltrate that includes mononuclear
cells and granulocytes– the majority of which are neutrophils
[7,8,9]. Additionally, microabscesses within the cornified layer
were readily observed in skin sections (Figure 2a). CCR2
2/2 mice
injected with IL-23 display many of these same characteristics –
epidermal acanthosis, hyperkeratosis and a mixed dermal in-
flammatory infiltrate. However, several differences in the histology
of IL-23-injected WT and CCR2
2/2 skin were evident. First,
CCR2
2/2 mice developed increased epidermal thickening com-
pared to WT mice (Figure 2a, 3a). Additionally, whereas WT mice
developed parakeratosis, the stratum corneum of CCR2
2/2 mice
lacked nuclei (Figure 2a). Moreover, flow cytometric analysis
demonstrated that although both IL-23-injected WT and
CCR2
2/2 skin displayed increased accumulation of inflammatory
dendritic cells (CD11c
+ CD11b
+ Ly6c
+) compared to PBS-injected
control mice, more dendritic cells were identified in the ears of
WT than CCR2
2/2 mice (Figure 3b). Finally, while there was
a mixed dermal inflammatory infiltrate in the ears of both WT
mice and CCR2
2/2 mice (Figure 2a), a greater percent of
neutrophils were present in the inflamed skin of WT mice
(Figure 3c). In contrast, an abundance of eosinophils (Figure 2a,
3d) and mast cells (Figure 2b, 3e) accumulated in the ears of
CCR2
2/2 mice suggesting the development of a Th2-type
immune response resembling atopic dermatitis [42,43].
CCR2 Ligands are Expressed in WT and CCR2
2/2 IL-23-
injected Skin
The chemokine receptor CCR2 binds multiple murine ligands:
CCL2, CCL7 and CCL12 [25]. Real time RT-PCR analysis of
WT ears demonstrated that CCL2, CCL7 and CCL12 mRNA
were most highly expressed on day 3–6 and then diminished by
day 12 after initiation of IL-23 injections (Figure 4a). These results
demonstrate that CCR2 ligands are expressed within the ears of
IL-23-injected WT mice and could recruit CCR2
+ cells. The
CCR2 ligands were expressed at least as highly in the ears of IL-
23-injected CCR2
2/2 as WT mice on day 6 (Figure 4b). Thus,
although CCR2
2/2 cells cannot respond to CCR2 ligands, these
results demonstrate that CCR2 is not required for CCR2 ligand
production. At day 12, the CCR2 ligands remained elevated in
CCR2
2/2 ear skin compared to WT ear skin, perhaps as
a compensatory mechanism for CCR2 deficiency or as a lack of
CCR2 ligand scavenging in the absence of CCR2
+ cells. Of note,
CCL7 also signals through CCR3 [44,45], a chemokine receptor
that remains intact in CCR2
2/2 mice and is expressed on
basophils, mast cells and eosinophils [46], providing a potential
mechanism for the increased recruitment of eosinophils into
CCR2
2/2 skin.
IL-22 is Expressed in IL-23-injected WT and CCR2
2/2 Ear
Skin
Depending on the disease model, the cytokine IL-22 has been
reported to have pro- or anti-inflammatory roles. Recent studies
suggest that IL-22 negatively regulates allergic responses. For
example, in a model of allergic airway inflammation, IL-22
decreased eosinophilia and Th2 cytokine production [47]. In
contrast, in the IL-23-induced psoriasis model, IL-22 is required
for the development of dermal inflammation and acanthosis [8]. In
this model, psoriatic skin pathology requires early T cell-
independent production of IL-22 for the subsequent, sustained T
cell-dependent inflammation [9]. CCR2 is expressed on innate
cells as well as activated Th17 cells, and so we examined whether
CCR2 deficiency reduced IL-22 production in IL-23-injected ears.
However, real-time RT-PCR analysis did not reveal any
significant difference in the expression of IL-22 in the ears of
WT and CCR2
2/2 mice either early (day 6) or late (day 12)
following the initiation of intradermal IL-23 injections (Figure 5).
Recent studies demonstrate that IL-22-producing T cells are
present in both psoriatic and chronic atopic dermatitis lesions
[48,49]. IL-22 induces keratinocyte proliferation and epidermal
hyperplasia, and so may contribute to the epidermal thickening
that we observe in both IL-23-injected WT and CCR2
2/2 skin.
Figure 1. IL-23 injection induces increased inflammation in
CCR2
2/2 mice compared to WT mice. Ears of CCR2
2/2 and WT mice
were injected every other day with 20 mL PBS alone or containing
500 ng IL-23. Ear thickness was measured one day following each
injection. Data are from at least 13 mice/group total in three separate
experiments. *p,0.01 versus all other groups.
doi:10.1371/journal.pone.0058196.g001
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PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e58196Figure 2. Eosinophils and mast cells accumulate in ears of IL-23-injected CCR2
2/2 mice. (A) H&E-stained sections of ears from IL-23-
injected WT and CCR2
2/2 mice at day 12. a, acanthosis; h, hyperkeratosis; p, parakeratosis; o, orthokeratosis; d, dermal inflammatory infiltrate; s;
spongiosis; m, intracorneal microabscess. Enlargements of the boxed areas within the WT IL-23 or CCR2
2/2 IL-23 image are displayed below the
corresponding photo. Black arrows indicate eosinophils. Green arrows indicate neutrophils. (B) Toluidine blue-stained sections of ear from IL-23-
injected WT and CCR2
2/2 mice at day 12. Arrows indicate mast cells.
doi:10.1371/journal.pone.0058196.g002
IL-23 Induces Th2 Inflammation in CCR2
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Previous studies of inflammatory responses in CCR2
2/2 mice
have observed increased Th2 cytokine production, with a corre-
sponding decrease in Th1 cytokine expression. Although we did
not detect a significant difference in the expression of IL-22 in the
IL-23-injected ears of WT and CCR2
2/2 mice, we reasoned that
a decrease in other Th17 or in Th1 cytokines, or an increase in
Th2 cytokines might explain the increased ear swelling and
eosinophilia observed in CCR2
2/2 IL-23-injected mouse skin.
WT and CCR2
2/2 mice were injected intradermally in the ear
every other day with IL-23, and on day 12, the injected ear skin
was isolated and analyzed for mRNA expression of Th1 (IFN-c),
Th2 (IL-4, IL-5, IL-13, TSLP) and Th17 (IL-17a, IL-17f)
cytokines. In this model of cutaneous inflammation, we did not
detect any difference in the expression of IFN-c in the ears of IL-
23-injected WT and CCR2
2/2 mice. Similarly, expression of IL-
17A and IL-17F were comparable in mice of both genotypes
Figure 3. Increased epidermal thickness and accumulation of eosinophils and mast cells in ears of IL-23-injected CCR2
2/2
compared to WT mice. (A) Average epidermal thickness was measured on H&E-stained sections. *p,0.02. Data are from two independent
experiments with three-four mice/group. (B) Ears were digested with collagenase and recovered leukocytes were analyzed by flow cytometry to
determine numbers of inflammatory dendritic cells (CD11c
+ CD11b
+ Ly6c
+) within ears of IL-23 injected WT and CCR2
2/2 mice. *p,0.05. Data are
from one experiment with three mice/group. Average percent neutrophils (C) and eosinophils (D) among leukocytes in H&E sections of ears from IL-
23-injected WT and CCR2
2/2 mice at day 12. (E) Average percent mast cells among leukocytes in toluidine blue sections of ears from IL-23-injected
WT and CCR2
2/2 mice at day 12. Slides were imaged (x200, original magnification) and numbers of eosinophils or neutrophils among leukocytes
were counted. Data are from four mice/genotype with at least three fields counted per mouse. *p,0.05; **p,0.005.
doi:10.1371/journal.pone.0058196.g003
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Th2 cytokine responses [50,51], but we failed to detect its
expression in either WT or CCR2
2/2 mice (Figure 6a). However,
quantitative RT-PCR analysis demonstrated that ears of CCR2
2/
2 mice expressed increased IL-4 mRNA compared to ears of WT
mice (Figure 6a). Of note, although we detected increased IL-4
mRNA expression in IL-23-injected CCR2
2/2 ears, WT and
CCR2
2/2 draining lymph nodes and ears contained comparable
numbers of IL-4-secreting T cells (Figure 6b). However, we did
measure increased mRNA expression of TSLP – a cytokine known
to promote and amplify Th2-type immune responses [52,53], in
the ears of CCR2
2/2 mice (Figure 6a). Additionally, tissue lysate
ELISA demonstrated increased TSLP protein expression in the
ears of CCR2
2/2 mice compared to WT mice (Figure 6c),
providing a possible mechanistic link to the increased Th2-type
immune response observed in these mice. Immunofluorescence
staining confirmed TSLP expression by epidermal cells within IL-
23-injected ears of both WT and CCR2
2/2 mice (Figure 6d). We
did not detect any specific TSLP staining in the dermis. Given the
epidermal hyperplasia observed in CCR2
2/2 mice, the increased
TSLP detected in IL-23-injected CCR2
2/2 mouse skin is likely
produced by keratinocytes, although other cell types may also
contribute to its production.
Figure 4. CCR2 ligands are expressed in IL-23-injected WT and CCR2
2/2 mouse ears. (A) On days 0, 3, 6, 9 and 12, CCL2, CCL7 and CCL12
mRNA were measured by real-time RT-PCR from ears of PBS-injected or IL-23-injected WT mice. Average of three mice. (B) On day 6 and 12, CCL2,
CCL7 and CCL12 mRNA was measured by real-time RT-PCR from ears of WT and CCR2
2/2 IL-23-injected mice. Day 6 results are an average of 11 mice
in 3 experiments. Day 12 results are an average of 8 mice in 2 experiments. *p,0.02.
doi:10.1371/journal.pone.0058196.g004
Figure 5. IL-22 mRNA is expressed in IL-23-injected CCR2
2/2
mouse ears. On days 6 and 12, IL-22 mRNA was measured by real-time
RT-PCR from ears of WT PBS-injected or WT and CCR2
2/2 IL-23-injected
mice. Day 6 results are an average of 11 mice per genotype in 3
experiments. Day 12 results are an average of 14 mice per genotype in 4
experiments.
doi:10.1371/journal.pone.0058196.g005
IL-23 Induces Th2 Inflammation in CCR2
2/2 Mice
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e58196Figure 6. Increased TSLP and IL-4 in ears of IL-23-injected CCR2
2/2 compared to WT mice. On day 12, (A) mRNA of indicated cytokines
was measured by real-time RT-PCR from ears of WT PBS-injected or WT and CCR2
2/2 IL-23-injected mice. Average of 11 mice per genotype in 3
experiments. *p,0.01. (B) Intracellular cytokine staining for IL-4 on gated CD3
+ CD4
+ T cells following stimulation with PMA and ionomycin was
performed and day 12 and analyzed by flow cytometry. Number of IL-4
+ CD3
+ CD4
+ T cells in draining lymph node (left panel) or IL-23-injected ear
(right panel). (C) TSLP was measured by tissue ELISA of ears isolated from PBS-injected or IL-23-injected WT and CCR2
2/2 mice. Average of 3 mice per
genotype. *p,0.005 CCR2 KO IL-23 vs. all other groups. (D) Representative immunofluorescence staining of ear skin isolated on day 12 from IL-23-
injected WT C57Bl/6 or CCR2
2/2 mice. Sections were stained with Ig isotype control antibody or anti-TSLP (x600, original magnification). Data are
reflective of 3 mice per genotype.
doi:10.1371/journal.pone.0058196.g006
IL-23 Induces Th2 Inflammation in CCR2
2/2 Mice
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58196Discussion
In this study, we examined the role of the chemokine receptor
CCR2 in a murine model of IL-23-induced psoriasis. The CCR2
ligand CCL2 is expressed by keratinocytes in psoriatic plaques
[26,27], suggesting a potential role for CCR2 in psoriasis
pathogenesis. In WT mice, intradermal IL-23 injection produces
IL-22-dependent psoriasiform pathology, including acanthosis and
dermal inflammatory infiltrates [8]. Here, we find that although
IL-22 mRNA expression was comparable in the ears of IL-23-
injected CCR2
2/2 mice and WT mice, ears of CCR2
2/2 mice
eventually became more inflamed with increased ear swelling and
epidermal thickening. This increased inflammation correlated with
increased cutaneous TSLP and IL-4 expression and increased
numbers of eosinophils within the skin of CCR2
2/2 mice
compared to WT mice.
Previous studies have also detected increased Th2-type immune
responses in CCR2
2/2 mice compared to WT mice using models
of infection [34], inflammation [28,35] and transplant [36]. The
increased Th2 responses observed in CCR2
2/2 mice have been
correlated with decreased Th1-type responses. Since Th1-type and
Th2-type cytokines are counter-regulatory [54], it has been
speculated that the decreased Th1 response seen in CCR2
2/2
mice leads to an increased Th2 response in these mice [55,56].
However, in the IL-23 model of cutaneous inflammation we found
comparable levels of Th1 (IFN-c) and Th17 (IL-17, IL-22)
cytokines in the inflamed skin of WT and CCR2
2/2 mice. Rather,
the increased Th2-type response we observed in CCR2
2/2 mice
correlated with increased cutaneous TSLP expression.
TSLP is an IL-7-like cytokine produced by several cell types,
including keratinocytes [52], dendritic cells [57,58] and basophils
[59]. TSLP promotes Th2-type immune responses through
stimulation of dendritic cells [52,53], as well as by direct
stimulation of CD4
+ T cell [60] and mast cell [61] Th2 cytokine
production. Additionally, TSLP promotes eosinophil survival and
cytokine secretion [62]. Mice injected intradermally with TSLP
[63] or transgenic for keratinocyte-specific TSLP expression [64]
display hallmark features of atopic dermatitis, including Th2
cytokine production, localized edema, acanthosis, hyperkeratosis
and a dermal mononuclear cell infiltrate rich in eosinophils and
mast cells. In this study, we found that TSLP was increased in the
skin of CCR2
2/2 mice compared to WT mice. Similar to mice
injected intradermally with TSLP or genetically engineered to
overexpress TSLP in keratinocytes, the increased TSLP expression
seen in CCR2
2/2 mice correlated with development of an atopic
dermatitis-like cutaneous inflammation. We found that a Th2-type
immune response, including increased IL-4 expression and
accumulation of eosinophils and mast cells developed in IL-23-
injected CCR2
2/2 mouse skin, likely as a result of increased
TSLP expression, but independent of an increased accumulation
of Th2 cells. Similarly, mice overexpressing TSLP but lacking T
cells also develop atopic dermatitis [64].
While TSLP instructs dendritic cells to promote the differen-
tiation of naı ¨ve T cells into Th2 effector cells, we did not observe
an increase in Th2 cell numbers in IL-23 injected skin or draining
lymph nodes of CCR2
2/2 mice. However, TSLP also acts on
innate immune cells, including mast cells and eosinophils to
promote Th2-type immune responses [61,62]. We do not yet
know whether TSLP acts upstream to direct, or downstream to
amplify the Th2 response in CCR2
2/2 mice. CCR2 deficiency
may change the composition of cells within the inflamed skin, and
thereby the cytokines that regulate TSLP expression. In our
studies, IL-23 may induce the recruitment of IL-4-producing
eosinophils into the skin through the regulation of CCL7 [65],
a CCR3 ligand [44,45]. CCR3 remains intact in CCR2
2/2 mice
and is expressed on basophils, mast cells and eosinophils [46],
providing a potential mechanism for the recruitment of eosinophils
and mast cells into CCR2
2/2 skin. Indeed, we detected increased
CCL7 expression in CCR2
2/2 mice compared to WT mice. In
parallel, IL-23 may promote the development of Th17 cells, which
induce IL-1 and TNFa production. Synergy of IL-4 with these
inflammatory cytokines could induce TSLP production by
keratinocytes [66], resulting in the amplification of the cutaneous
Th2-type immune response. To our knowledge, this is the first
study to correlate the increased Th2-type immune response in
CCR2
2/2 mice with increased TSLP production.
In conclusion, CCR2 deficiency exacerbates cutaneous in-
flammation induced by intradermal IL-23 injection. Although
CCR2 blockade has ameliorated several inflammatory diseases by
skewing T cell responses to Th2, intradermal injection of CCR2
2/
2 mice results in an atopic dermatitis-like lesion rather than
a psoriasis-like lesion. CCR2-deficiency leads to more severe
cutaneous inflammation with increased TSLP and Th2-type
cytokine production as well as eosinophil and mast cell infiltration.
These results suggest that increased TSLP expression in CCR2
2/
2 mice may contribute to the propensity of these mice to develop
exaggerated Th2-type immune responses.
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